New site aims to enhance biopharmaceutical manufacturing capabilities.
- Samsung Biologics to establish a new Gateway Labs site.
- Collaboration with Lilly aims to strengthen pharmaceutical manufacturing.
- New facility will support advancements in biopharmaceuticals.
Samsung Biologics has announced a strategic partnership with Lilly to establish a new Gateway Labs site in Korea. This collaboration aims to enhance capabilities in biopharmaceutical manufacturing and support the growing demands of the biotech industry. The Samsung Biologics Gateway Labs will serve as a hub for innovative manufacturing processes.
The new facility is expected to facilitate advancements in the production of biopharmaceuticals, ensuring that both companies can meet increasing market demands efficiently. By combining their expertise, Samsung Biologics and Lilly plan to drive progress in the industry, particularly in the field of biologics research and development.
This partnership highlights the commitment of both organizations to enhance their manufacturing capabilities in Korea. The establishment of the Gateway Labs is anticipated to play a crucial role in advancing biopharmaceutical innovations and delivering quality healthcare solutions.
